Acusphere
Lexington, Massachusetts, United States
About Acusphere
Acusphere is a specialty pharmaceutical company, primarily focused on the development of Imagify™ (perflubutane polymer microspheres) injectible suspension, a cardiovascular drug for the detection of coronary artery disease. Acusphere is in the process of seeking regulatory approval of Imagify in Europe, and negotiating a Special Protocol Assessment with FDA for an additional trial required for U.S. approval. Imagify was created using Acusphere’s proprietary porous microparticle technology, which was also used to create three other drugs which have begun clinical development – AI-525 for acute pain, AI-850 for oncology and AI-128 for asthma. AI-525 and AI-850 were sold to Cephalon in transactions totaling $31 million. AI-128 was developed in collaboration with Elan, who contributed $7.5 million to the program. Acusphere’s technology has the potential to create a wide variety of new drugs by reformulating hydrophobic drugs and creating sustained release formulations of existing drugs.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $29.0M
- Funding stage: IPO
- Last round: Post-IPO Debt (Feb 2012)
- Ticker: otcpink:ACUS
- Website: acusphere.com
- Phone: (617) 925-3444
Industries & Categories
Biopharma, Biotechnology, Pharmaceutical
Canonical: https://fsome.com/organization/acusphere-2600404 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.